Related Experiment Videos
Loxapine succinate: a controlled double-blind study in chronic schizophrenia
Diseases of the Nervous System
|July 1, 1975
Summary
Loxapine succinate and chlorpromazine showed similar efficacy in treating chronic schizophrenia over 12 weeks. Both antipsychotics effectively reduced illness severity and psychopathology with comparable side effect profiles.
Area of Science:
- Psychiatry
- Clinical Pharmacology
Background:
- Schizophrenia is a chronic mental disorder requiring effective treatment.
- Loxapine succinate and chlorpromazine are established antipsychotic medications.
Purpose of the Study:
- To compare the efficacy and safety of loxapine succinate and chlorpromazine in hospitalized patients with chronic schizophrenia.
Main Methods:
- A 12-week, double-blind study involving 50 hospitalized chronic schizophrenic patients.
- Assessment of psychopathology using the Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression (CGI) scale, and Nurses' Observation Scale for Inpatient Evaluation (NOSIE).
Main Results:
- Both loxapine succinate and chlorpromazine demonstrated significant improvements in BPRS scores and reduced illness severity on the CGI scale.
- Chlorpromazine showed significant improvement in "manifest psychosis" on the NOSIE scale, while loxapine succinate improved "global severity."
- No significant differences were observed between the two drugs in overall psychopathology reduction or on most BPRS, CGI, or NOSIE measures.
Conclusions:
- Loxapine succinate and chlorpromazine exhibit comparable efficacy in treating chronic schizophrenia.
- The side effect profiles of both medications were similar, with behavioral, extrapyramidal, and sedative symptoms being most frequent.
- Neither drug showed evidence of serious adverse effects based on vital signs and laboratory data.